A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery

NCT05316688 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

8

Enrollment

OTHER

Sponsor class

Stopped Terminated due to suboptimal delineation of fluorescence between tumor and native oral cavity mucosa.

Conditions

Oral Cavity Squamous Cell Carcinoma
Stage I Lip and Oral Cavity Cancer AJCC v8
Stage II Lip and Oral Cavity Cancer AJCC v8
Stage III Lip and Oral Cavity Cancer AJCC v8
Stage IVA Lip and Oral Cavity Cancer AJCC v8

Interventions

PROCEDURE: Near Infrared Imaging
PROCEDURE: Therapeutic Conventional Surgery
DRUG: Tozuleristide

Sponsor

University of Washington

Collaborators

[object Object]